Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ECCS 50

Next Previous
Drug Profile

ECCS 50

Alternative Names: Adipose-derived stem and regenerative cell (ADRC) therapy - Plus Therapeutics; Adipose-derived stem cells - Plus Therapeutics; ADRCs - Plus Therapeutics; Cytori Cell Therapy; ECCI-50; ECCO-50; ECCS-50; Habeo; Habeo Cell Therapy

Latest Information Update: 28 Mar 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cytori Therapeutics
  • Developer Aix-Marseille University; Assistance Publique - Hopitaux de Marseille; Nagoya University; Plus Therapeutics
  • Class Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Raynaud's disease; Scleroderma
  • New Molecular Entity No

Highest Development Phases

  • Phase III Scleroderma
  • No development reported Crohn's disease; Scars; Urinary incontinence

Most Recent Events

  • 28 Mar 2023 No recent reports of development identified for clinical-Phase-Unknown development in Crohn's-disease in France (Parenteral)
  • 28 Mar 2023 No recent reports of development identified for clinical-Phase-Unknown development in Scars in Unknown
  • 06 Apr 2021 No development reported - Phase-III for Urinary incontinence in Japan (Transurethral)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top